TREATMENT PATTERNS, HEALTHCARE RESOURCE USE, AND COSTS AMONG US PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFRm) METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC) AFTER DISCONTINUATION OF OSIMERTINIB

被引：0

作者：

Moore-Schiltz, L. ^{[1
]}

McMorrow, D. ^{[2
]}

Chambers, J. ^{[1
]}

Pulungan, Z. ^{[1
]}

Teigland, C. ^{[1
]}

Marrett, L. ^{[3
]}

机构：

[1] Inovalon, Bowie, MD USA

[2] Inovalon, Scarborough, ME USA

[3] Daiichi Sankyo Inc, Basking Ridge, NJ USA

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE371

引用

页码：S125 / S126

页数：2

共 50 条

[31] COMPARISON OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TESTED AND NOT-TESTED METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) PATIENT COHORTS IN EUROPE
Narayanan, S.
Gallo, F.
VALUE IN HEALTH, 2015, 18 (07) : A365 - A365
[32] Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?
Zarogoulidis, Paul
Papadopoulos, Vasilis
Maragouli, Elena
Papatsibas, George
Huang, Haidong
JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2771 - 2773
[33] The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer
Ramanathan, Siddharth
Shen, Nathan
Kestin, Larry
Balaraman, Savitha
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
[34] Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
Passiglia, Francesco
Raez, Luis E.
Rolfo, Christian
JOURNAL OF THORACIC DISEASE, 2018, 10 : S1076 - S1080
[35] Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?
Casaluce, Francesca
Gridelli, Cesare
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S370 - S372
[36] Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer
Li, Yuan-yuan
Lam, Sze-kwan
Mak, Judith Choi-wo
Zheng, Chun-yan
Ho, James Chung-man
LUNG CANCER, 2013, 81 (03) : 354 - 361
[37] Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care
Wu, Fang
Zeng, Yue
Neal, Joel W.
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (10) : 2853 - 2855
[38] The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer
Brade, Anthony M.
TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S55 - S57
[39] FIRST LINE GEFITINIB IN YOUNGER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Elhidsi, Mia
Hudoyo, Ahmad
Andarini, Sita
RESPIROLOGY, 2015, 20 : 100 - 100
[40] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
Jamal-Hanjani, Mariam
Spicer, James
CLINICAL CANCER RESEARCH, 2012, 18 (04) : 938 - 944

← 1 2 3 4 5 →